This protocol describes detailed practical procedures for generating 3D intact and perfusable microvascular network that connects to microfluidic channels without appreciable leakage. This advanced 3D microvascular network model incorporates different stages of vascular development including vasculogenesis, endothelial cell (EC) lining, sprouting angiogenesis, and anastomosis in sequential order. The capillary network is first induced via vasculogenesis in a middle tissue chamber and then EC linings along the microfluidic channel on either side serve as artery and vein. The anastomosis is then induced by sprouting angiogenesis to facilitate tight interconnection between the artery/vein and the capillary network. This versatile device design and its robust construction methodology establish a physiological microcirculation transport model of interconnected perfused vessels from artery to vascularized tissue to vein.
Introduction
The cardiovascular system plays a vital role in maintaining homeostasis of the human body, which allows blood to circulate throughout body for gas exchange and mass transportation to maintain organ viability. In order to construct a more physiological organon-a-chip, it is critical to be able to construct a functional 3D microvasculature system with a closed network of arteries, veins, and capillaries [1, 2] .
On that basis, different research groups around the world have applied microfluidics to develop 3D in vitro microvascular models * These authors contributed equally to this work. that physiologically mimic the vascular biology [3] . For cell and tissue engineering applications, microfluidic technologies were first used to confine cells in patterned, restricted regions to create microenvironments with well-controlled cellular interactions. More recently, microfluidic researchers have demonstrated control of the complex microenvironment at physiological levels by regulating chemical factors (molecular gradients etc.) or mechanical factors (interstitial flow etc.). Currently, there are two strategies to develop a 3D microvascular model. One strategy is to create microfabricated vessel scaffolds with specific geometries and dimensions, and line their inner surface with endothelial cells (ECs). The advantage of this method is that the vessel diameter can be precisely controlled, and the tightness of EC junctions can be flexibly adjusted by imposing different shear stress parameters on these lined ECs [4] [5] [6] . The other strategy is to seed cells in 3D extracellular matrices (ECMs) to allow spontaneous formation and remodeling of vascular networks through vasculogenesis and angiogenesis, which can closely mimic vascular development in vivo [7] [8] [9] [10] [11] [12] . However, the microvascular network pattern embedded in 3D ECMs cannot be controlled and easily perfused [13] .
In this protocol, we introduce an advanced 3D microvascular network model with intact perfused physiological blood vessels. By combining the two strategies mentioned above, we have engineered a system with tight interconnections between artery/vein and the capillary microvasculature network without non-physiological leakage. The major procedures involved in this advanced 3D microvascular network model are: (1) The capillary network formation is induced via vasculogenesis in a middle tissue chamber, and ECs are lined along the microfluidic channel on both sides to serve as the artery and vein. (2) Anastomosis is induced bidirectionally through sprouting angiogenesis to guarantee a good connection between the lined ECs along the microfluidic channels and the capillaries inside the tissue chamber [14] . Flow of fluorescent microparticles confirms perfusability of the lumenized microvascular network. In addition, minimal leakage of 70 kDa FITC-dextran confirms physiologic integrity of the interconnections between the artery/vein and the capillary network, which is critically important for drug screening applications [15] . This model can provide a promising avenue for future integration of multiple organs-on-a-chip through the vascular interface between arteries and veins [16, 17] .
Building on our previous publications [18] [19] [20] [21] [22] , this protocol seeks to provide detailed practical procedures to develop a complete and contiguous 3D perfused microvascular network without nonphysiological leakage. The enabling technologies detailed here include microfluidic device design and microfabrication, cell-seeded hydrogel preparation and loading, maintenance of cell culture in the microfluidic chip, flow control for different stages of vascular development, and immunostaining of the vascular network.
Methods
1. After simulation of designed chip ( Fig. 1) , print out the photomask with high resolution.
2. Put a 3-in. silicon wafer into 5% HF for cleaning its surface, followed by a deionized water rinse, and dehydrate the wafer by placing it into the oven maintained at 120 °C for 10 min.
3. Place the silicon wafer on the spinner chuck of spin coater and apply vacuum (see Note 4).
4.
Pour proper amount of SU-8 2050 on the center of the wafer (see Note 5).
5.
Start the spin coater, and spin the wafer at 500 rpm for 20 s and then increase the speed to 130 × g for 30 s to achieve the desired thickness of 100 μm.
6. Place the photoresist-coated wafer into the oven or on the hotplate at 65 °C for 5 min.
7. Transfer the wafer to a hotplate/oven at 95 °C for 20 min (see Note 6).
8.
Remove the baked wafer from the hotplate/oven and cool down to room temperature (RT) gradually.
9. Cover the photoresist-coated wafer with the photomask and bring them in tight contact (see Note 7). 10 . Expose the wafer under UV light at 230 mJ/cm 2 .
11. Move the exposed wafer to oven at 65 °C for 5 min, and then bake the wafer at 95 °C for 10 min.
12. Place the wafer into photoresist developer for proper time (see Note 8).
13. Spray the wafer with developer to remove the undeveloped photoresist, especially at the small features, and then wash the wafer with IPA.
14. Dry the wafer with pressurized filter nitrogen or air.
15. Place the SU-8 silicon mold into the desiccator and put a small drop of silane on coverslip close to the wafer, and evacuate the chamber to induce the evaporation of silane (see Note 9). 16 . Remove the silicon mold from desiccator after overnight silanization.
1. Pour silicone elastomer base and curing agent at a weight ratio of 10:1 (base: curing agent) into an empty disposable plastic cup.
2. Mix the base and curing agent vigorously using a disposable plastic knife until the PDMS mixture appears opaque.
3. Attach the silicon mold to the bottom surface of petri dish with double-sided tape. 4. Use compressed nitrogen to gently blow off dust particles from the silicon mold.
Fabrication of SU-8 Silicon Mold and Its Silanization

Fabrication and Assembly of PDMS Microfluidic Device
5.
Pour approximately 20-25 g of the PDMS mixture onto the silicon mold inside the petri dish, and approximately 5 g of the PDMS mixture into an empty petri dish to fabricate a thin PDMS sheet.
6. Place both petri dishes into a vacuum desiccator to degas until the PDMS mixture becomes transparent.
7. Transfer the petri dishes covered with lid to the oven at 60 °C for 4-5 h to fully cure PDMS.
8. Remove the petri dishes from the oven and cool down to RT.
9. Carefully remove the PDMS microfluidic chip from the silicon mold and the PDMS sheet from the petri dish by cutting around the perimeter of the device using a scalpel and trim to proper size. 10 . Punch holes at inlets and outlets of the PDMS microfluidic chip using a hole puncher.
11. Remove debris inside the punched holes using a compressed nitrogen gun.
Clean both sides of the PDMS microfluidic chip and PDMS
sheet with transparent tape.
13. Treat the cleaned PDMS microfluidic chip and PDMS sheet inside a plasma cleaner for 3 min at 250-300 mTorr.
14.
Quickly remove these two plasma-treated pieces from the plasma cleaner and bond them together. 15 . Place the bonded two-layer device into the oven at 120 °C for 10 min. 16 . Treat the PDMS sheet of bonded device and a glass slide (or a glass coverslip) inside the plasma cleaner for 1 min at 250-300 mTorr.
17. Quickly bond the PDMS sheet and the glass slide to make a three-layer microfluidic device ( Fig. 2a ).
18. Place the bonded three-layer device into the oven at 120 °C for 10 min. 19 . Place pipette tips into all inlets and outlets of bonded microfluidic device to prevent PDMS seeping into these punched holes.
20. Cut off the bottom of plastic cryo vials using a scalpel.
21.
Immerse the edge of bottomless plastic vials into PDMS mixture and attach them to all medium inlets and outlets of the microfluidic device. 22 . Place the assembled microfluidic device into the oven at 60 °C overnight to fully cure PDMS ( Fig. 2b ).
23. Sterilize the microfluidic device by autoclaving at 121 °C for 30 min before experiment ( Fig. 2c ).
1. Warm EGM-2, DPBS, and trypsin in water bath at 37 °C for 20-30 min before experiment.
2. Wash ECFC-ECs and NHLFs with 5-10 mL of HBSS 1-2 times.
3. Aspirate wash solution and add 2 mL of trypsin for each T75 flask to harvest cells.
4. Agitate and place the flasks in incubator for 20-30 s.
5.
Remove the flasks from incubator and check under microscope for cell detachment. 8. Centrifuge cells at 300 × g for 3 min.
Cell Harvesting and Cell-Seeded Hydrogel Preparation
9. Aspirate the supernatants and reconstitute cells in EGM-2 at a density of 10 6 cells/mL. 10 . Prepare cell matrix solution: The desired cell concentration for ECFC-ECs and NHLFs is both 5 × 10 6 cells/mL of fibrinogen solution, for a combined concentration of 10 7 cells/mL. For example, after harvesting each cell type, resuspend the cell pellet in medium at 10 6 cells/mL, take out 500 μL of ECFC-ECs and 500 μL of NHLFs and combine in a single tube.
11. Centrifuge cells at 300 × g for 3 min and resuspend the combined pellet in 100 μL of sterile filtered fibrinogen solution (see Note 10).
1. Aliquot 2 μL of thrombin into a 0.5 mL snap cap tube for each device planned to load (see Note 11).
2. Put a filter pipette tip of 200 μL at one end of gel loading pore to prevent spilled out hydrogel.
3. Gently mix and take out 15 μL of cell-seeded fibrinogen suspension without any air bubble (see Note 12).
4.
Quickly mix with the thrombin droplet 2-3 times in the 0.5 mL snap cap tube without generating air bubbles (see Note 13).
5.
Quickly inject the mixed suspension into the loading pore and gently push the gel through to the other side with steady pipette pressure (see Note 14).
6. Slowly place the microfluidic device down and twist the pipette tip out of the micropipettor to eject (see Note 15).
7.
Leave the device inside the hood for 1-2 min before bringing out to check under the microscope. During this time, load the next device.
8. After checking under microscope, transfer the device into incubator at 37 °C and incubate for 10-15 min to let the gel fully polymerize ( Fig. 3 ). While waiting for gel polymerization, thaw laminin solution from 4 °C to RT 30-45 min before loading medium.
9. After incubation, pipette 3-4 μL of laminin solution into the cell lining inlets to coat the inner surface of both microfluidic channels adjacent to the tissue chamber (see Note 16).
Cell-Seeded Hydrogel and Medium Loading into Device
10. Block all cell lining inlets and outlets with PDMS plugs (see Note 17).
11
. Take 200 μL of full supplement EGM-2 and load through one medium inlet inside the plastic vial (see Note 18).
12. Wait until medium droplet spills out to the medium outlet inside the other plastic vial.
13. Repeat steps 11 and 12 to load medium into the other side channel.
14. Slowly twist pipette tips out of the medium inlets and let medium form droplets. 18. After 1 h, check back to see if there is any air bubble in both side channels. If there is, remove it by pipetting medium through the medium inlet to push air bubble out (see Note 21).
1. Keep the device inside incubator with full supplement EGM-2 for 2 days before changing medium.
2. On day 2 post-embedding, warm EGM-2 without VEGF/ bFGF for 20-30 min in the water bath.
3. Aspirate old medium, leaving a small amount of liquid inside each plastic vial to avoid air bubble. Fig. 3 Cell-seeded fibrinogen gel loading. The optimized communication pore design can precisely control the gel at the vertexes of communication pores with a flat gel-air interface without bursting into the microfluidic channels. This enabled the formation of a smooth EC monolayer on the gel interface at the communication pore, a critical condition for EC lining and sprouting angiogenesis. Scale bars, 100 μm. Reproduced from Wang et al. [21] with permission from RSC 4. Add fresh medium (EGM-2 without VEGF/bFGF) to each vial with the same height as that of step 15 in Subheading 3.4.
Medium Changing and Vasculogenesis
5.
Change medium for the device in similar manner every other day.
6. ECFC-ECs will form vascular fragments as early as day 2, and continue to develop into a capillary network through day 5. By day 7, the capillary network is lumenized and interconnected ( Fig. 4a-c) .
Laminin coating inside the microfluidic channels promotes
ECs from the tissue chamber migrating through the communication pore outward and partially lining the inner surface of the channels (Fig. 4d ).
1. Harvest ECFC-ECs and resuspend cells in EGM-2 for a concentration of 2 × 10 7 cells/mL.
2.
Remove medium from the plastic vials, leaving a small amount to avoid air bubble. 4. Slowly remove plugs from cell lining inlet and outlet and add 1-2 μL of medium to cover the inlet and outlet and prevent air bubbles.
EC Lining, Sprouting Angiogenesis, and Anastomosis
5. Mix and take out 5 μL of cell suspension using a micropipettor and insert the pipette tip into the cell lining inlet.
6. Insert a bent syringe needle connected with an empty 1 mL syringe into the cell lining outlet (see Note 22).
7.
Place the device under the microscope.
8. Slowly pull syringe to withdraw cells from cell lining inlet toward cell lining outlet. Cells will flow through and accumulate inside the side microfluidic channel by the obstacle array near the cell lining outlet (see Note 23).
9.
Monitor under the microscope and stop withdrawing when cells have filled up a whole microfluidic channel.
10. Alternatively, cells can be withdrawn through the cell lining outlet using a micropipettor instead of the bent syringe needle. Set micropipettor for 5 μL volume, insert an empty pipette tip to the cell lining outlet, and withdraw cells by releasing the micropipettor button.
Bring device into the incubator and incubate for 2 h to allow
ECs to adhere to all inner side microfluidic channel walls.
12. Reverse flow gently from the cell lining outlet toward cell loading inlet to remove non-adhering ECs by gently pipetting 1-2 μL of medium through the cell lining outlet blocked with a filtered, empty pipette tip.
13. Remove pipette tips at the cell lining inlet and outlet and block with plugs.
14.
Reestablish the same medium flow as that of step 15 in Subheading 3.4.
15. Adhered ECs elongate to form a monolayer in response to shear stress generated by the pressure drop along the side microfluidic channel (Fig. 5 ). 16 . After the EC lining process, a confluent EC monolayer will form on the gel interface at the communication pore (Fig. 6a ). 18. Switch medium supplied to the microfluidic channel with higher pressure to full supplement EGM-2 to induce a positive VEGF gradient that promotes sprouting angiogenesis. 19 . Lined ECs at the cell-matrix interface invade into the ECM and form microvascular sprouts as early as 24 h post-lining (Fig. 6b ). (Fig. 6c ).
Reverse the interstitial flow direction across tissue chamber by
Highly branched and abundant sprouts extend into ECM
21.
Anastomosis with tight interconnection is a bidirectional process. From inside the tissue chamber, ECs migrate outward to the laminin-coated microfluidic channel to connect with the EC-lined microfluidic channel during vasculogenesis. From the outer microfluidic channel, the lined ECs invade into the ECM and form sprouts to connect with the capillaries inside the tissue chamber during sprouting angiogenesis (Fig. 6d ).
22.
Repeat the EC lining process for the other side microfluidic channel 2 days after lining the first channel. An intact and perfusable microvascular network of artery/vein and capillaries can be developed in this microfluidic device via a multistep process through 12 days (Fig. 7) .
1. Remove medium from all plastic vials, leaving a small amount at the bottom to avoid air bubble.
2. Add microparticle solution to the plastic vial with the highest hydrostatic pressure (23 mm H 2 O) and sterile PBS to the other plastic vials. (Fig. 8a) . 4. After dextran perfusion, replace old PBS containing dextran with sterile PBS and allow flow through for 20 min (Fig. 8b) .
Monitor microparticle moving inside vessel lumen under an inverted (epifluorescent) microscope
Microparticle Perfusion
5.
Replace sterile PBS with fresh medium and continue culture in incubator. Fig. 7 Formation of intact and perfusable microvascular network with artery/vein and capillary network by multistep processes throughout 12 days. Vasculogenesis of ECs-mCherry started to occur 3 days after introducing cell-seeded fibrin gels into the tissue chamber. ECs-BFP were added to an outer channel at this point.
70 kDa-FITC Dextran Perfusion
Immunostaining of Vascular Network
After 24 h post-lining, these lined ECs-BFP began to elongate and form connections with ECs-mCherry through the communication pore. On day 5, the other channel was lined with ECs-BFP and the direction of interstitial flow, which was also the transendothelial flow direction, was reversed to promote remodeling of the capillaries inside the tissue chamber and to stimulate angiogenic sprouting of lined ECs. In addition, ECs-mCherry also migrated out from the tissue chamber and interlaced with ECs-BFP lining the microfluidic channel. ECs-BFP along both microfluidic channels continued to proliferate, elongate, and form connections with the microvascular network inside the tissue chamber thereafter. By day 12, a fully lumenized capillary network inside the tissue chamber had anastomosed with both EC-lined microfluidic channels to form the intact microvascular network. Scale bars, 100 μm. Reproduced from Wang et al. [21] with permission from RSC 9. Remove blocking solution from all plastic vials, leaving a small amount at the bottom to avoid air bubbles.
10. Carefully remove the plastic vials without disrupting the blocking solution droplets.
11. Insert pipette tips with antibody staining solution to the medium inlets. Place empty pipette tips to the medium outlets (see Note 27).
12.
Gently withdraw antibody dilution from the outlets using a micropipettor. Monitor for a small amount of liquid moving upward through the empty pipette tips.
13. Aspirate excess blocking solution at the inlets and outlets and leave the device at 4 °C overnight.
14. Reverse the flow direction by switching antibody dilution from the inlet to the outlet and leave at 4 °C for 4-6 h. 15 . After primary antibody staining, wash the device with sterile PBS for 4-6 h (Fig. 9a) . 17. Repeat the antibody staining process from steps 11-13.
18. After secondary antibody staining, wash device multiple times with sterile PBS to remove background. 19 . For nuclei staining, replace washing PBS with DAPI solution and leave at 4 °C overnight.
20. Wash device multiple times with sterile PBS to remove excess DAPI (Fig. 9b ).
Notes
1. Make extra fibrinogen to account for sterile filter after dissolved in DPBS.
2. Do not vortex the tube to dissolve the fibrinogen powder.
3. Do not thaw laminin stock solution directly to RT. For longterm storage, keep laminin at −80 °C.
4.
Place silicon wafer at the center of spinner chuck to ensure a uniform thickness of the photoresist layer.
5.
Slowly perform this step to prevent air bubble formation in the poured photoresist layer.
6. Keep the hotplate/oven on a flat surface to prevent the unwanted changes of photoresist film.
7. Ensure the ink printed side of photomask is in contact with the photoresist layer on the wafer.
Fig. 9
Immunostaining image of a capillary network inside a tissue chamber. (a) CD31 immunostaining. CD31 (PECAM-1) is a cellular adhesion and signaling receptor that is highly expressed at endothelial cell-cell junctions, and has been shown to play an important role in maintenance of vascular barrier integrity. This CD31 immunostaining highlighted the integrity of the vascular network formed in our device. (b) DAPI nuclear staining. Reproduced from Wang et al. [21] with permission from RSC 8. Placing the container with the developer and wafer into an ultrasonic instrument will highly accelerate the development speed.
9. Perform the silanization procedure inside a ventilated chemical fume hood. 10 . Prepare no more than 200 μL of cell-fibrinogen mixture per aliquot. If more cell-matrix volume is needed, divide combined cell pellet into multiple aliquots to assure desired cell density.
11. Ensure thrombin droplet is at the bottom of the tube.
12. Change pipette tips between mixing the solution and loading the solution into the device. 13 . Perform this step quickly to avoid damaging the gel or creating uneven polymerization, as the cell matrix solution will begin polymerizing quickly upon mixing with thrombin.
14.
Press the push-button smoothly and evenly.
15. Do not eject pipette tip by pushing the eject button on the micropipettor. Otherwise, gel will burst out.
16. Pre-coating side microfluidic channels with laminin before adding culture medium is crucial to ensure EC adherence to PDMS for EC lining, and stimulate EC migration outward from the tissue chamber to anastomose with the EC-lined microfluidic channels.
17. PDMS plug is fabricated by dipping pipette tip into PDMS mixture and allowing to fully cure at 60 °C overnight.
18. Perform this step slowly to avoid damaging the gel inside tissue chamber. 19 . Calculate the volume based on the diameter of vial. 20. To minimize the medium evaporation from the plastic vials and maintain humidity, prepare a large pipette tip box with sterile water and a smaller pipette tip rack (or a small plastic petri dish) to place the device on top and separate from the water. Sterile water should be changed every other day.
21.
Removing air bubbles formed inside the microfluidic channel as soon as detected is crucial after loading device. Air bubbles can block medium flow and damage gel inside the tissue chamber.
22. Bend a 21-gauge blunt end needle and attach to the syringe. Do not use slant end needle.
23. Withdraw slowly to avoid introducing air bubble into the microfluidic channel.
24. Do not perfuse dextran for more than 90 min under fluorescent microscope.
25. Thaw fresh 4% PFA for optimal fixing. Do not freeze and thaw 4% PFA multiple times.
26. Device with sterile PBS can be stored at 4 °C for 1-2 weeks after fixing. Seal storage container with Parafilm to prevent evaporation.
27. Prepare 100-150 μL of antibody dilution per device. Set up a temporary hydrostatic pressure to allow antibodies flowing through the device. Typically, 70-80 μL of antibody dilution is for the highest pressure inlet, and 30-40 μL is required for the second highest pressure inlet.
